Scientific deep-dive
Retatrutide for MASH and MASLD: What the Phase 2a Liver-Fat Data Show
Retatrutide is not FDA-approved. Its only human liver data is a Phase 2a substudy (Sanyal 2024, n=98): liver fat fell 82.4% at 12 mg vs +0.3% on placebo at 24 weeks, and 86% normalized. Phase 3 liver data are pending. How it compares with Rezdiffra and Wegovy.
The honest answer: Retatrutide is not FDA-approved for MASH, MASLD, or anything else. The only human data in fatty liver disease is a single Phase 2a substudy (n=98) measuring liver fat by MRI-PDFF at 24 weeks[1]. No Phase 3 retatrutide-in-MASH results have been reported as of October 2026; a Phase 3 liver-outcomes trial that includes retatrutide (SYNERGY-Outcomes) began recruiting in October 2025[12].
At a glance
- Retatrutide is Eli Lilly’s investigational triple GIP/GLP-1/glucagon receptor agonist. It is not approved for any indication, including MASH/MASLD.
- The only human MASLD data is Sanyal et al., Nat Med 2024 (PMID 38858523) — a 48-week Phase 2a substudy in 98 adults with obesity and ≥10% liver fat[1].
- At 24 weeks, mean relative liver-fat reduction was −42.9% (1 mg), −57.0% (4 mg), −81.4% (8 mg), −82.4% (12 mg) vs +0.3% placebo (all P < 0.001)[1].
- Liver fat normalization (<5%) at 24 weeks: 27% / 52% / 79% / 86% across the four doses vs 0% placebo[1].
- The Sanyal Phase 2a used MRI-PDFF, not biopsy. MASH resolution and fibrosis improvement endpoints were not assessed.
- The current FDA-approved option for biopsy-confirmed MASH with F1B–F3 fibrosis is Rezdiffra (resmetirom), approved March 2024[11]. Semaglutide (Wegovy) was approved for MASH in August 2025 based on ESSENCE Phase 3[3].
- Compounded retatrutide for MASH is not a legitimate pathway — it is not on the FDA bulk substances list, has no FDA-reviewed safety package, and is in active investigation.
What MASH and MASLD mean
MASLD (metabolic dysfunction-associated steatotic liver disease) is the 2023 nomenclature for what used to be called NAFLD — excess fat accumulation in the liver (≥5% of hepatocytes) in a patient with at least one cardiometabolic risk factor (overweight/obesity, type 2 diabetes, hypertension, dyslipidemia). MASH (metabolic dysfunction-associated steatohepatitis) is the more advanced form: fatty liver plus inflammation and hepatocyte injury (ballooning) on biopsy. MASH can progress through fibrosis stages F1 → F2 → F3 → F4 (cirrhosis), with higher-stage fibrosis driving the liver-related mortality risk. See our Wegovy MASH evidence review for the terminology change in detail and the ESSENCE Phase 3 results.
Where retatrutide stands
Retatrutide is investigational. In the Phase 3 obesity program (TRIUMPH), TRIUMPH-1 (NEJM) and TRIUMPH-2 (Lancet) were published in September 2026, Lilly announced TRIUMPH-3 topline results in July 2026, and TRIUMPH-4 read out in December 2025; Lilly plans to submit its FDA application in the first quarter of 2027, for obesity, sleep apnea and knee osteoarthritis pain, not MASH. For the liver, Lilly's Phase 3 SYNERGY-Outcomes master protocol (NCT07165028) began recruiting in October 2025: about 4,500 adults with MASLD at increased risk of liver outcomes, with separate retatrutide-vs-placebo and tirzepatide-vs-placebo arms. Its primary endpoint is time to the first major adverse liver outcome, and primary completion is estimated for August 2030[12]. The only human MASLD evidence is the Sanyal Phase 2a substudy nested within the parent obesity Phase 2 program[1]. For the broader retatrutide evidence base (Phase 2 weight loss, TRIUMPH-4, mechanism, and access considerations), see our retatrutide triple-agonist evidence review and the TRIUMPH-1 before-and-after evidence.
What Sanyal Phase 2a showed
Sanyal et al., Nat Med 2024 (PMID 38858523), reported a randomized, double-blind, placebo-controlled Phase 2a substudy of once-weekly subcutaneous retatrutide in adults with obesity-related MASLD[1]. Verified design and results:
- Sample size: n = 98 (substudy of the 48-week Phase 2 obesity trial in participants with MASLD and ≥10% liver fat)
- Doses: 1 mg, 4 mg, 8 mg, 12 mg subcutaneously once weekly, or placebo
- Duration: 48 weeks of dosing
- Primary endpoint: mean relative change from baseline in liver fat by MRI-PDFF at 24 weeks
Mean relative change in liver fat at 24 weeks was −42.9% (1 mg), −57.0% (4 mg), −81.4% (8 mg), −82.4% (12 mg) versus +0.3% with placebo (all P < 0.001 vs placebo)[1]. Liver-fat normalization (defined as <5%) at 24 weeks was achieved by 27% / 52% / 79% / 86% of participants across the four reta arms versus 0% on placebo[1].
Magnitude comparison
Mean relative change in liver fat (MRI-PDFF) from baseline at 24 weeks — retatrutide Phase 2a MASLD substudy (Sanyal 2024, Nat Med, n=98). Values are absolute magnitude of percent change. All retatrutide arms P < 0.001 vs placebo. Note: placebo arm showed a +0.3% increase (rendered here as 0.3 for chart legibility).[1]
- Placebo0.3 % LF change+0.3% (slight increase)
- Retatrutide 1 mg42.9 % LF reduction
- Retatrutide 4 mg57.0 % LF reduction
- Retatrutide 8 mg81.4 % LF reduction
- Retatrutide 12 mg82.4 % LF reductionhighest dose; 86% achieved <5% LF
Two important caveats: (1) the primary endpoint was measured by MRI-PDFF, an imaging biomarker for liver fat content, not by paired liver biopsy. MASH resolution and fibrosis improvement — the histologic endpoints the FDA has used to approve resmetirom and semaglutide for MASH — were not assessed. (2) The Phase 2a abstract does not break out adverse-event or discontinuation rates within the MASLD substudy specifically; safety data for the parent obesity Phase 2 are in Jastreboff 2023 NEJM (PMID 37366315).
FDA-approved comparator: resmetirom (Rezdiffra), MAESTRO-NASH
On March 14, 2024 the FDA granted accelerated approval to resmetirom (Rezdiffra), a thyroid hormone receptor-beta agonist, as the first drug ever approved for MASH[11]. Approval was based on MAESTRO-NASH (Harrison et al., NEJM 2024, PMID 38324483; NCT03900429), a Phase 3 trial of 966 adults with biopsy-confirmed MASH and F1B, F2, or F3 fibrosis[2].
- NASH resolution with no worsening of fibrosis at week 52: 25.9% (80 mg) / 29.9% (100 mg) vs 9.7% placebo (P < 0.001 for both)[2]
- Fibrosis improvement ≥1 stage with no worsening of NAFLD activity score: 24.2% (80 mg) / 25.9% (100 mg) vs 14.2% placebo (P < 0.001 for both)[2]
Resmetirom is currently the only drug approved on a histologic MASH endpoint via paired biopsy. It is indicated for adults with non-cirrhotic MASH and moderate-to-advanced (F2/F3) fibrosis.
Cross-trial vs semaglutide ESSENCE Phase 3
Sanyal et al., NEJM 2025 (ESSENCE, PMID 40305708), reported the 72-week interim analysis of Phase 3 semaglutide 2.4 mg weekly in adults with biopsy-confirmed MASH and F2/F3 fibrosis[3]. Verified key findings:
- Resolution of steatohepatitis without worsening of fibrosis: 62.9% semaglutide vs 34.3% placebo (estimated difference 28.7 percentage points; 95% CI 21.1–36.2; P < 0.001)[3]
- Reduction in fibrosis without worsening of steatohepatitis: 36.8% vs 22.4% (difference 14.4 pp; P < 0.001)[3]
- Mean body-weight change: −10.5% vs −2.0% placebo[3]
ESSENCE supported the August 2025 FDA approval of Wegovy for non-cirrhotic MASH with moderate-to-advanced fibrosis — the first GLP-1 with an FDA-approved liver indication.
Cross-trial vs tirzepatide SYNERGY-NASH Phase 2
Loomba et al., NEJM 2024 (SYNERGY-NASH, PMID 38856224), reported the 52-week Phase 2 trial of tirzepatide in 190 adults with biopsy-confirmed MASH and F2/F3 fibrosis[4]. Verified primary endpoint:
- MASH resolution without worsening of fibrosis : 44% (5 mg) / 56% (10 mg) / 62% (15 mg) vs 10% placebo (P < 0.001 for all)[4]
Tirzepatide has not yet received an FDA-approved MASH indication; a Phase 3 program is ongoing.
How retatrutide’s liver-fat signal sits in context
The retatrutide Phase 2a numbers are striking on the MRI-PDFF endpoint — up to 82.4% mean relative liver-fat reduction at the 12 mg dose, with 86% of participants reaching the <5% normalization threshold by 24 weeks[1]. But MRI-PDFF reduction is not the same endpoint as the histologic MASH-resolution and fibrosis-improvement endpoints the FDA uses to approve MASH drugs. Resmetirom, semaglutide, and tirzepatide all carry biopsy-based readouts; retatrutide has only an imaging biomarker in MASLD so far. Whether the Phase 2a liver-fat signal will translate into histologic MASH resolution and fibrosis improvement in a Phase 3 trial is currently unknown.
Preclinical mechanism support
Two recent animal studies support a plausible biological rationale for retatrutide in MASH:
- Viebahn 2025 (Am J Physiol Gastrointest Liver Physiol, PMID 41056349): in an accelerated mouse model of diet-induced steatohepatitis with a fructose binge, retatrutide improved steatohepatitis histology[5].
- Briand 2026 (Obesity, PMID 41741376): in two-species (mouse and hamster) diet-induced obese MASH models, retatrutide produced multiple metabolic benefits[6].
These are preclinical findings. They establish biological plausibility but do not predict efficacy in humans. Reviews of the broader anti-obesity-drug landscape in MASLD (Concepción- Zavaleta 2025[7]), GLP-1-based medications (Son 2026[8]), glucagon-receptor pharmacology (Elmendorf 2026[9]), and engineered multi-agonist design (Cho 2026[10]) all flag retatrutide as a high-interest candidate but consistently note the absence of Phase 3 MASH outcome data.
What is not yet known
- No Phase 3 retatrutide-in-MASH results have been reported as of October 2026; SYNERGY-Outcomes (NCT07165028) is still recruiting, with primary completion estimated for August 2030[12].
- No biopsy-confirmed histologic endpoint. The Sanyal Phase 2a used MRI-PDFF only. MASH resolution and fibrosis improvement — the endpoints the FDA has consistently required for MASH drug approval — have not been assessed for retatrutide.
- No liver-outcome data. There is no published retatrutide data on cirrhosis development, hepatocellular carcinoma, liver transplantation, or all-cause mortality in MASH patients.
- No head-to-head trial. There is no randomized comparison of retatrutide vs resmetirom, semaglutide, or tirzepatide in MASH.
- Safety in MASH-specific populations. The Sanyal Phase 2a was nested in the obesity trial. Glucagon receptor agonism raises mechanistic questions specifically relevant to hepatic and glycemic safety that will need dedicated MASH-population characterization. A related drug offers an early read on the glucagon approach: survodutide’s phase 3 liver-fat trial enrolled adults with obesity and at-risk MASLD, though most did not meet formal MASH criteria and it says nothing directly about retatrutide.
Practical takeaway
For a patient with biopsy-confirmed MASH and moderate-to-advanced fibrosis (F1B–F3) who wants pharmacologic treatment today, the FDA-approved options are resmetirom (Rezdiffra) — approved specifically on a MASH histologic endpoint — and semaglutide 2.4 mg (Wegovy), approved August 2025 for non-cirrhotic MASH with moderate-to-advanced fibrosis based on ESSENCE Phase 3[3]. Tirzepatide has promising Phase 2 SYNERGY-NASH data but is not yet FDA-approved for MASH[4].
Retatrutide is investigational and not currently prescribable for MASH. Compounded retatrutide is not a legitimate access pathway — it is not on the FDA bulk substances list, has not been through FDA review, and is in active clinical investigation. Patients interested in retatrutide for fatty liver disease should discuss enrolling in a clinical trial with a hepatologist rather than seeking compounded supply.
Patients worried about GLP-1 effects on the liver should also see our review of the question do GLP-1s cause liver damage — the trial evidence consistently shows reduced liver fat and improved liver enzymes, not harm.
Further reading
- Top GLP-1 MASH/MASLD studies
- SYNERGY-NASH trial deep-dive (tirzepatide for MASH/NASH)
- Top retatrutide studies
Key terms, explained
New to GLP-1s? Tap any term for a quick, plain-English definition.
- Retatrutide · Drugs and brands
- Triple agonist · Mechanism
- Tirzepatide · Drugs and brands
- Wegovy · Drugs and brands
- Zepbound · Drugs and brands
- GLP-1 receptor · Mechanism
- GIP receptor · Mechanism
Frequently Asked Questions
References
- 1.Sanyal AJ, Kaplan LM, Frias JP, Brouwers B, Wu Q, Thomas MK, Harris C, Schloot NC, Du Y, Mather KJ, Haupt A, Hartman ML. Triple hormone receptor agonist retatrutide for metabolic dysfunction-associated steatotic liver disease: a randomized phase 2a trial. Nat Med. 2024. PMID: 38858523.
- 2.Harrison SA, Bedossa P, Guy CD, Schattenberg JM, Loomba R, Taub R, Labriola D, Moussa SE, Neff GW, Rinella ME, Anstee QM, Abdelmalek MF, Younossi Z, Baum SJ, Francque S, Charlton MR, Newsome PN, Lanthier N, Schiefke I, Mangia A, Pericàs JM, Patil R, Sanyal AJ, Noureddin M, Bansal MB, Alkhouri N, Castera L, Rudraraju M, Ratziu V; MAESTRO-NASH Investigators. A Phase 3, Randomized, Controlled Trial of Resmetirom in NASH with Liver Fibrosis. N Engl J Med. 2024. PMID: 38324483.
- 3.Sanyal AJ, Newsome PN, Kliers I, Østergaard LH, Long MT, Kjær MS, Cali AMG, Bugianesi E, Rinella ME, Roden M, Ratziu V; ESSENCE Study Group. Phase 3 Trial of Semaglutide in Metabolic Dysfunction-Associated Steatohepatitis. N Engl J Med. 2025. PMID: 40305708.
- 4.Loomba R, Hartman ML, Lawitz EJ, Vuppalanchi R, Boursier J, Bugianesi E, Yoneda M, Behling C, Cummings OW, Tang Y, Brouwers B, Robins DA, Nikooie A, Bunck MC, Haupt A, Sanyal AJ; SYNERGY-NASH Investigators. Tirzepatide for Metabolic Dysfunction-Associated Steatohepatitis with Liver Fibrosis. N Engl J Med. 2024. PMID: 38856224.
- 5.Viebahn GK, Hartmann P, Schaefer L, Roeb E, Roderfeld M. Retatrutide improves steatohepatitis in an accelerated mouse model of diet-induced steatohepatitis with a fructose binge. Am J Physiol Gastrointest Liver Physiol. 2025. PMID: 41056349.
- 6.Briand F, Sulpice T. Retatrutide Shows Multiple Metabolic Benefits in Diet-Induced Obese MASH Mouse and Hamster Models. Obesity (Silver Spring). 2026. PMID: 41741376.
- 7.Concepción-Zavaleta MJ, Quiroz-Aldave JE, Coronado-Arroyo JC, Concepción-Urteaga LA, Paz-Ibarra J. Efficacy and safety of anti-obesity drugs in metabolic dysfunction-associated steatotic liver disease: An updated review. World J Gastroenterol. 2025. PMID: 41025003.
- 8.Son JW. Novel GLP-1-based Medications for Type 2 Diabetes and Obesity. Endocr Rev. 2026. PMID: 41054801.
- 9.Elmendorf AJ, Hodson DJ, Tomas A. IUPHAR review: From foe to friend: Repurposing glucagon to treat obesity and type 2 diabetes. Pharmacol Res. 2026. PMID: 41478576.
- 10.Cho YK, Lee YH. Engineered nutrient-stimulated hormonal multi-agonists for precision targeting of obesity and metabolic disorders. Clin Mol Hepatol. 2026. PMID: 41297910.
- 11.U.S. Food and Drug Administration. FDA Approves First Treatment for Patients with Liver Scarring Due to Fatty Liver Disease (Rezdiffra / resmetirom). FDA Press Announcement, March 14, 2024. 2024. https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-patients-liver-scarring-due-fatty-liver-disease
- 12.Eli Lilly and Company. A Master Protocol of Multiple Agents in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (SYNERGY-Outcomes) (NCT07165028). ClinicalTrials.gov. 2025. https://clinicaltrials.gov/study/NCT07165028
Related research
Survodutide for Fatty Liver: What the Phase 3 Nature Medicine Trial Shows
In the phase 3 SYNCHRONIZE-MASLD trial, survodutide 6.0 mg cut liver fat by at least 30% in 68.5% of adults at week 48, versus 28.6% on placebo. What that means, what the biopsy data add, and what the trial cannot show about scarring or liver outcomes.
8 min read
Retatrutide TRIUMPH Phase 3: Latest Pipeline Update
In the TRIUMPH-1 phase 3 trial, Lilly's retatrutide produced up to 25.0% weight loss at 80 weeks, and 18.8% in people with type 2 diabetes in TRIUMPH-2. Lilly plans to file with the FDA in Q1 2027. Open safety questions and the access timeline are covered.
11 min read
GLP-1 for Fatty Liver & MASH: The Patient Action Plan
If you've been told you have fatty liver (MASLD/MASH), the next step is fibrosis staging by FibroScan or MRI-PDFF. Wegovy is approved for F2-F3 MASH per ESSENCE, Rezdiffra is the alternative, and tirzepatide is still in phase 2.
13 min read
Wegovy for MASH, MAFLD & Fatty Liver: FDA Approval & ESSENCE Evidence Review
In August 2025 the FDA approved Wegovy (semaglutide 2.4 mg weekly) for adults with non-cirrhotic MASH and moderate-to-advanced fibrosis based on the ESSENCE phase 3 trial. ESSENCE results, MASH/MASLD terminology, eligibility, Zepbound status, and AASLD lifestyle adjuncts.
15 min read
Wegovy for MASH: ESSENCE Trial Results + FDA Approval Pathway
Sanyal's ESSENCE trial showed semaglutide 2.4 mg resolved MASH without worsening fibrosis in 62.9% of patients. The FDA Wegovy MASH approval changes Medicaid + Medicare pathways. We map the trial, the F2/F3 fibrosis criteria, and the hepatology workflow.
12 min read
Tirzepatide vs Retatrutide: GIP/GLP-1 vs Triple Agonist Evidence
Tirzepatide hits GLP-1 + GIP. Retatrutide adds glucagon for additional energy expenditure. We walk through the mechanism math, SURMOUNT-1 vs phase 3 TRIUMPH-1 cross-trial magnitude, and the trade-offs in HR + nausea + weight loss.
11 min read
Where to get GLP-1 safely: vetted online providers
Vetted telehealth providers that prescribe online. We compare pricing, form, and states served.
No insurance needed · vetted by our editors
WeightLossRankings.org is reader-supported. When you buy through links on our site, we may earn an affiliate commission. How we make money
Found
Medication-included compounded GLP-1 on 28-day cash plans, plus insurance help for brand-name GLP-1s
Read full review →From $289/4 wks
billed per 4 weeks
Oak
Compounded semaglutide and tirzepatide at a low starting price, with a full price list before you sign up
Read full review →From $200/mo
starting dose
From $99/mo